Effect of L-dopa In Subacute Back Pain Population

Completed · Phase 4 · Has a placebo group

Conditions studied: Sub-acute Back Pain

In brief

This study aims to determine if early treatment with Carbidopa/Levodopa and Naproxen in individuals with sub-acute back pain (SBP) is associated with changes in blocking transition to chronic back pain (CBP).

Key facts

Study ID

NCT01951105

Run by

Northwestern University

People needed

72

Starts

2015-02-24

Expected to finish

2017-09-25

Last updated by the study team

2021-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, over the age of 18 years, (no racial/ethnic restrictions)
• Must have a history of low back pain for a minimum of 4 weeks and a maximum of 12 weeks with signs and symptoms of radiculopathy: positive straight leg raising test with dermatomal radiation and/or myotomal weakness and/or reflex asymmetry; pain must radiate into buttock or below
• Must have a high risk phenotype for chronification of back pain (evaluated at baseline T1-MRI, DTI-MRI, and fMRI scans)
• Must have an average pain score over a 5 day period (average of \~15 measures on smartphone app) immediately preceding the baseline visit of ≥ 5 (on a 0-10 NRS) at the baseline visit
• Must be willing to read and able to understand instructions as well as PROs
• Must be in generally stable health Must sign an informed consent document after complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate

You may not qualify if…

• Previous (distinct) episodes of back pain onset (more than 3 distinct episodes of back pain lasting for a total of more than 4 weeks) in the previous year
• Evidence of rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures, chronic spinal stenosis, prior back surgery and history of tumor of the spine
• Low back pain associated with any systemic signs or symptoms, e.g., fever, chills
• Other comorbid chronic pain conditions such as fibromyalgia or neuropathic pain secondary to diabetes or post-herpes zoster
• Chronic neurologic conditions, including Parkinson's disease, Alzheimer's disease, and other conditions associated with dementia
• Significant other medical disease such as congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy
• Diabetes Type I or Type II
• History of glaucoma or narrow angle glaucoma
• Presence of undiagnosed skin lesions or history of melanoma
• Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease
• History of myocardial infarction with residual cardiac arrhythmia
• History of gastrointestinal bleeding or peptic ulcer
• Diagnosis of current depression (assessed via BDI, total > 28 are excluded) or psychiatric disorder requiring treatment, or such a diagnosis in the previous 6 months
• Use of therapeutic doses of antidepressant medications (i.e., tricyclic antidepressants, SSRIs, SNRIs; low doses used only in the evening for sleep will be allowed if dose is not changed)
• Current use of recreational drugs or recent history of alcohol abuse (pattern of drinking having social, financial or physical consequences) or drug abuse
• Any change in medication for back pain in the last 30 days
• High dose opioid prophylaxis, defined as > 50mg morphine equivalent/day
• Use of MAOIs, currently or within the past 2 weeks
• Prior use of Levodopa
• Use of any of the following drugs: bromocryptine, linezolid, metoclopramide, phenothiazines,promethazine/codeine, isoniazid, rifampin, pyrazinamide
• Oral iron supplementation
• Contraindications to use of study product, based on any of the following:
• Hypersensitivity to Carbidopa/Levodopa or other constituents of the Carbidopa/Levodopa capsules
• Hypersensitivity to lactose or other constituents of the placebo capsules
• Hypersensitivity to Naproxen or other constituents of the Naproxen capsules

Where it is running

• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.